In the present study, sarpogrelate suppressed TAC-induced phosphorylation of ERK1/2, but it did not completely suppress eccentric hypertrophy, suggesting the possibility that sarpogrelate does not inhibit the activation of MEK1 in cardiac hypertrophy. The gene discussed is MAPK3; the disease is cardiac hypertrophy.